PreciThera, Inc., a Montreal, Canada-based precision medicine company, dedicated to the design and development of innovative biological therapeutics for the treatment of orphan bone diseases, completed a CAD$36m (US$29m) Series A financing.
Backers included Sanderling Ventures, Arix Bioscience, Fonds de solidarité FTQ, CTI Life Sciences and Emerillon Capital.
The company intends to use the funds to develop novel molecules and to advance its lead candidate through IND and into clinical studies with the goal to establish clinical proof of concept and identify a path to registration.
Co-founded by Dr. Philippe Crine and Dr. Susan Schiavi in 2016 and led by Pierre Beauparlant, CEO, PreciThera is dedicated to the design and development of innovative biological therapeutics for the treatment of orphan bone diseases that cannot be treated via traditional protein replacement therapies. The company utilizes a combination of informatics-based tools to combine information from RNA sequencing and from genomic and clinical databases to validate the major pathway responsible for clinical symptoms in rare genetic disorders.